United Therapeutics (UTHR) Total Non-Current Liabilities (2009 - 2026)

United Therapeutics has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $599.1 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $599.1 million, down 16.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $599.1 million (down 16.96% YoY), and the FY2025 annual result was $560.6 million, down 24.05% from the prior year.
• Total Non-Current Liabilities came in at $599.1 million for Q1 2026 at United Therapeutics, up from $560.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 billion in Q3 2023 to a low of $527.1 million in Q2 2025.
• The 5-year median for Total Non-Current Liabilities is $1.1 billion (2024), against an average of $922.7 million.
• Across the five-year window, Total Non-Current Liabilities advanced 11.49% in 2023 and slumped 43.46% in 2025, its largest moves.
• United Therapeutics' Total Non-Current Liabilities stood at $1.1 billion in 2022, then retreated by 3.39% to $1.1 billion in 2023, then slumped by 33.17% to $738.1 million in 2024, then slipped by 24.05% to $560.6 million in 2025, then advanced by 6.87% to $599.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $599.1 million (Q1 2026), $560.6 million (Q4 2025), and $546.3 million (Q3 2025), per Business Quant data.